Pfizer Biontech Coronavirus Vaccine
- All
- News
- Videos
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
EU Watchdog Reviews Adapted Pfizer Jab. Target: Omicron
Europe's medicines watchdog said Wednesday it has started to review an adapted version of Pfizer/BioNTech's anti-Covid jab in order to better protect against specific variants of the virus, including Omicron.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
Pfizer To Seek US Approval For Covid Vaccine For Children Under 5: Report
Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
Pfizer Covid Vaccine For Children In EU To Be Available In Two Weeks
The EU's main Covid vaccine provider, BioNTech/Pfizer, will have jabs available for children in the bloc in two weeks' time, European Commission chief Ursula von der Leyen said Wednesday.
-
BioNTech And Pfizer Expect New Variant Impact Data "Within 2 Weeks"
Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.
-
Pfizer Requests US Emergency Authorisation For Covid Booster For Adults
Drugmakers Pfizer and BioNTech announced Tuesday they have formally submitted a request asking US officials for emergency authorization of their Covid-19 booster vaccine for people aged 18 and older.
-
Pfizer Submits Data For Approval Of Covid Jab For Ages 5 To 11 In Europe
Pfizer and BioNTech said Friday they had submitted data to the EU's medicines watchdog for the approval of their coronavirus vaccine for children aged 5 to 11, following a similar step in the United States.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
Government Won't Buy Pfizer, Moderna Shots As Local Output Jumps: Report
India will not buy COVID-19 shots from Pfizer/BioNTech and Moderna, three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped.
-
Pfizer Covid Vaccine Safe For Children Aged 5-11: Clinical Trial Results
Pfizer and BioNTech on Monday said clinical trial results showed their coronavirus vaccine was "safe, well tolerated" and produced a "robust" immune response in children aged five to 11, adding that they would seek regulatory approval shortly.
-
UK Schoolchildren Aged 12-15 Years To Be Offered Covid Vaccine First Dose
Schoolchildren aged between 12 and 15 years will be offered a first dose of the Pfizer/BioNTech COVID-19 vaccine starting next week, the UK government has announced after the country's Chief Medical Officers gave their go-ahead for the jabs for young
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
EU Watchdog Reviews Adapted Pfizer Jab. Target: Omicron
Europe's medicines watchdog said Wednesday it has started to review an adapted version of Pfizer/BioNTech's anti-Covid jab in order to better protect against specific variants of the virus, including Omicron.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
Pfizer To Seek US Approval For Covid Vaccine For Children Under 5: Report
Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
Pfizer Covid Vaccine For Children In EU To Be Available In Two Weeks
The EU's main Covid vaccine provider, BioNTech/Pfizer, will have jabs available for children in the bloc in two weeks' time, European Commission chief Ursula von der Leyen said Wednesday.
-
BioNTech And Pfizer Expect New Variant Impact Data "Within 2 Weeks"
Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.
-
Pfizer Requests US Emergency Authorisation For Covid Booster For Adults
Drugmakers Pfizer and BioNTech announced Tuesday they have formally submitted a request asking US officials for emergency authorization of their Covid-19 booster vaccine for people aged 18 and older.
-
Pfizer Submits Data For Approval Of Covid Jab For Ages 5 To 11 In Europe
Pfizer and BioNTech said Friday they had submitted data to the EU's medicines watchdog for the approval of their coronavirus vaccine for children aged 5 to 11, following a similar step in the United States.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
Government Won't Buy Pfizer, Moderna Shots As Local Output Jumps: Report
India will not buy COVID-19 shots from Pfizer/BioNTech and Moderna, three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped.
-
Pfizer Covid Vaccine Safe For Children Aged 5-11: Clinical Trial Results
Pfizer and BioNTech on Monday said clinical trial results showed their coronavirus vaccine was "safe, well tolerated" and produced a "robust" immune response in children aged five to 11, adding that they would seek regulatory approval shortly.
-
UK Schoolchildren Aged 12-15 Years To Be Offered Covid Vaccine First Dose
Schoolchildren aged between 12 and 15 years will be offered a first dose of the Pfizer/BioNTech COVID-19 vaccine starting next week, the UK government has announced after the country's Chief Medical Officers gave their go-ahead for the jabs for young
-
Moderna's Shot Creates Twice As Many Antibodies As Pfizer, Study Shows
Moderna Inc.'s Covid vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
